[go: up one dir, main page]

WO2008103431A3 - Dnai - liposomes - Google Patents

Dnai - liposomes Download PDF

Info

Publication number
WO2008103431A3
WO2008103431A3 PCT/US2008/002332 US2008002332W WO2008103431A3 WO 2008103431 A3 WO2008103431 A3 WO 2008103431A3 US 2008002332 W US2008002332 W US 2008002332W WO 2008103431 A3 WO2008103431 A3 WO 2008103431A3
Authority
WO
WIPO (PCT)
Prior art keywords
dnai
liposomes
cancer
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/002332
Other languages
French (fr)
Other versions
WO2008103431A2 (en
Inventor
Wendi Rodrigueza
Neal Clifford Goodwin
Govren James Patrick Mc
Donald Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sierra Oncology Inc
Original Assignee
ProNAi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProNAi Therapeutics Inc filed Critical ProNAi Therapeutics Inc
Publication of WO2008103431A2 publication Critical patent/WO2008103431A2/en
Publication of WO2008103431A3 publication Critical patent/WO2008103431A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides oligonucleotide compositions and methods for the treatment of cancer.
PCT/US2008/002332 2007-02-23 2008-02-21 Dnai - liposomes Ceased WO2008103431A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90297307P 2007-02-23 2007-02-23
US60/902,973 2007-02-23

Publications (2)

Publication Number Publication Date
WO2008103431A2 WO2008103431A2 (en) 2008-08-28
WO2008103431A3 true WO2008103431A3 (en) 2009-06-25

Family

ID=39631112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/002332 Ceased WO2008103431A2 (en) 2007-02-23 2008-02-21 Dnai - liposomes

Country Status (1)

Country Link
WO (1) WO2008103431A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
ES2419106T3 (en) 2005-12-01 2013-08-19 Pronai Therapeutics, Inc. Amphoteric liposome formulation
WO2009051712A1 (en) * 2007-10-15 2009-04-23 Pronai Therapeutics, Inc. Dnai amphoteric liposome formulation
EP2911650B1 (en) * 2012-10-29 2019-09-04 Agency For Science, Technology And Research A novel reagent for gene-drug therapeutics

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014172A1 (en) * 1996-10-04 1998-04-09 Board Of Regents, The University Of Texas System Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
WO2003073826A2 (en) * 2002-03-01 2003-09-12 Sagres Discovery, Inc Novel compositions and methods for cancer
US20050181037A1 (en) * 2002-05-24 2005-08-18 Neopharm, Inc. Cardiolipin compositions their methods of preparation and use
WO2007014150A2 (en) * 2005-07-22 2007-02-01 Neopharm, Inc. Method of administering liposomes containing oligonucleotides
WO2007031333A2 (en) * 2005-09-15 2007-03-22 Novosom Ag Improvements in or relating to amphoteric liposomes
WO2007149269A2 (en) * 2006-06-12 2007-12-27 Oncomethylome Sciences S.A. Methylation markers for early detection and prognosis of colon cancers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014172A1 (en) * 1996-10-04 1998-04-09 Board Of Regents, The University Of Texas System Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
WO2003073826A2 (en) * 2002-03-01 2003-09-12 Sagres Discovery, Inc Novel compositions and methods for cancer
US20050181037A1 (en) * 2002-05-24 2005-08-18 Neopharm, Inc. Cardiolipin compositions their methods of preparation and use
WO2007014150A2 (en) * 2005-07-22 2007-02-01 Neopharm, Inc. Method of administering liposomes containing oligonucleotides
WO2007031333A2 (en) * 2005-09-15 2007-03-22 Novosom Ag Improvements in or relating to amphoteric liposomes
WO2007149269A2 (en) * 2006-06-12 2007-12-27 Oncomethylome Sciences S.A. Methylation markers for early detection and prognosis of colon cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOI W-J ET AL: "Low toxicity of cationic lipid-based emulsion for gene transfer", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 25, no. 27, 1 December 2004 (2004-12-01), pages 5893 - 5903, XP004511128, ISSN: 0142-9612 *
LASIC D D: "Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 48, no. 2-3, 13 October 1997 (1997-10-13), pages 203 - 222, XP004125857, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
WO2008103431A2 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2008097561A8 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
PL1765391T3 (en) Bacterial compositions for the treatment of cancer
WO2006119295A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2008030883A3 (en) Treatment of cancer
PL2340042T3 (en) Methods and compositions for the treatment of cancer
WO2009092108A3 (en) Biomarkers for the diagnosis and treatment of pancreatic cancer
EP2049151A4 (en) Methods and compositions for the treatment of cancer
WO2008013589A3 (en) Treatment of ras-expressing tumors
WO2008112192A3 (en) Epha3 antibodies for the treatment of solid tumors
WO2008144223A3 (en) Triazolyl aminopyrimidine compounds
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2007081751A9 (en) Compositions and methods for the treatment of cancer
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2010141956A3 (en) Methods and compositions for the treatment of cancer
WO2010037095A3 (en) Agents and methods for the treatment of cancer
WO2011029639A3 (en) Compounds and methods for treating neoplasia
WO2008103431A3 (en) Dnai - liposomes
WO2008069976A3 (en) Compounds and methods for enzyme-mediated tumor imaging and therapy
WO2008144222A3 (en) Triazolyl aminopyrimidine compounds
WO2008085927A3 (en) Methods, compositions, and kits for the treatment of pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08725922

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08725922

Country of ref document: EP

Kind code of ref document: A2